270 related articles for article (PubMed ID: 33924120)
1. MicroRNAs in Medullary Thyroid Carcinoma: A State of the Art Review of the Regulatory Mechanisms and Future Perspectives.
Galuppini F; Censi S; Moro M; Carraro S; Sbaraglia M; Iacobone M; Fassan M; Mian C; Pennelli G
Cells; 2021 Apr; 10(4):. PubMed ID: 33924120
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC.
Shabani N; Razaviyan J; Paryan M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
Hum Pathol; 2018 Sep; 79():212-221. PubMed ID: 29885402
[TBL] [Abstract][Full Text] [Related]
3. Two GEO MicroRNA Expression Profile Based High-Throughput Screen to Identify MicroRNA-31-3p Regulating Growth of Medullary Thyroid Carcinoma Cell by Targeting RASA2.
Jiang M; Shi X; Zhu H; Wei W; Li J
Med Sci Monit; 2019 Jul; 25():5170-5180. PubMed ID: 31298226
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.
Lassalle S; Zangari J; Popa A; Ilie M; Hofman V; Long E; Patey M; Tissier F; Belléannée G; Trouette H; Catargi B; Peyrottes I; Sadoul JL; Bordone O; Bonnetaud C; Butori C; Bozec A; Guevara N; Santini J; Hénaoui IS; Lemaire G; Blanck O; Vielh P; Barbry P; Mari B; Brest P; Hofman P
Oncotarget; 2016 May; 7(21):30461-78. PubMed ID: 27036030
[TBL] [Abstract][Full Text] [Related]
5. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients.
Shabani N; Sheikholeslami S; Paryan M; Zarif Yeganeh M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
J Cell Physiol; 2020 Feb; 235(2):1366-1373. PubMed ID: 31297834
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic in medullary thyroid cancer: the role of microRNA in tumorigenesis and prognosis.
Manso J; Censi S; Mian C
Curr Opin Oncol; 2021 Jan; 33(1):9-15. PubMed ID: 33093335
[TBL] [Abstract][Full Text] [Related]
7. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
Chu YH; Lloyd RV
Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
[TBL] [Abstract][Full Text] [Related]
8. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.
Romeo P; Colombo C; Granata R; Calareso G; Gualeni AV; Dugo M; De Cecco L; Rizzetti MG; Zanframundo A; Aiello A; Carcangiu ML; Gloghini A; Ferrero S; Licitra L; Greco A; Fugazzola L; Locati LD; Borrello MG
Endocr Relat Cancer; 2018 Mar; 25(3):217-231. PubMed ID: 29298817
[TBL] [Abstract][Full Text] [Related]
9. Identification of microRNAs associated with medullary thyroid carcinoma by bioinformatics analyses.
Fu X; Fang J; Lian M; Zhong Q; Ma H; Feng L; Wang R; Wang H
Mol Med Rep; 2017 Jun; 15(6):4266-4272. PubMed ID: 28487941
[TBL] [Abstract][Full Text] [Related]
10. Identification and interaction analysis of key miRNAs in medullary thyroid carcinoma by bioinformatics analysis.
Zhang L; Lu D; Liu M; Zhang M; Peng Q
Mol Med Rep; 2019 Sep; 20(3):2316-2324. PubMed ID: 31322209
[TBL] [Abstract][Full Text] [Related]
11. miR‑592 acts as an oncogene and promotes medullary thyroid cancer tumorigenesis by targeting cyclin‑dependent kinase 8.
Liu T; Meng J; Zhang Y
Mol Med Rep; 2020 Oct; 22(4):3316-3326. PubMed ID: 32945439
[TBL] [Abstract][Full Text] [Related]
12. Assessment of
Pishkari S; Hadavi R; Koochaki A; Razaviyan J; Paryan M; Hashemi M; Mohammadi-Yeganeh S
Horm Mol Biol Clin Investig; 2021 Mar; 42(3):265-271. PubMed ID: 33769725
[TBL] [Abstract][Full Text] [Related]
13. Expression of MicroRNAs in Thyroid Carcinoma.
Zhu G; Xie L; Miller D
Methods Mol Biol; 2017; 1617():261-280. PubMed ID: 28540691
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome.
Mian C; Pennelli G; Fassan M; Balistreri M; Barollo S; Cavedon E; Galuppini F; Pizzi M; Vianello F; Pelizzo MR; Girelli ME; Rugge M; Opocher G
Thyroid; 2012 Sep; 22(9):890-6. PubMed ID: 22747440
[TBL] [Abstract][Full Text] [Related]
15. Role of tissue and circulating microRNAs and DNA as biomarkers in medullary thyroid cancer.
Chiacchiarini M; Trocchianesi S; Besharat ZM; Po A; Ferretti E
Pharmacol Ther; 2021 Mar; 219():107708. PubMed ID: 33091426
[TBL] [Abstract][Full Text] [Related]
16. Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy.
Vitale G; Dicitore A; Messina E; Sciammarella C; Faggiano A; Colao A
Recent Pat Anticancer Drug Discov; 2016; 11(3):275-82. PubMed ID: 27306881
[TBL] [Abstract][Full Text] [Related]
17. MiR-375: A prospective regulator in medullary thyroid cancer based on microarray data and bioinformatics analyses.
Shi L; Zhao SM; Luo Y; Zhang AW; Wei LH; Xie ZY; Li YY; Ma W
Pathol Res Pract; 2017 Nov; 213(11):1344-1354. PubMed ID: 29033189
[TBL] [Abstract][Full Text] [Related]
18. Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears.
Titov SE; Demenkov PS; Ivanov MK; Malakhina ES; Poloz TL; Tsivlikova EV; Ganzha MS; Shevchenko SP; Gulyaeva LF; Kolesnikov NN
Oncol Rep; 2016 Nov; 36(5):2501-2510. PubMed ID: 27666315
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma.
Chu YH; Hardin H; Schneider DF; Chen H; Lloyd RV
Exp Mol Pathol; 2017 Oct; 103(2):229-236. PubMed ID: 29107050
[TBL] [Abstract][Full Text] [Related]
20. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
